$IBBJ

IBBJ

$30.1

Small Cap Biotech ETF

No spam. We promise

Because Juniors Grow

Covid vaccines, cancer treatments, R&D for a healthier future. IBBJ captures the next gen strength of biotech and pharma in the space with greatest growth potential – small cap companies with big ideas.

IBBJ offers the investor liquid, transparent and low-cost* access to junior companies that are classified as either biotechnology or pharmaceutical. The ETF can be traded intraday, providing flexible yet targeted exposure to a potentially growing sector.

The underlying Nasdaq Junior Biotechnology Index tracks approximately 239 companies from over 16 countries.

The Nasdaq Junior Biotechnology Index is a modified market capitalization weighted index that tracks the performance of small-cap “junior” companies listed on the Nasdaq Stock Market® (Nasdaq®), which are under $5 billion of market capitalization. They must be classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

These are companies engaged in biotech research and development, the sale or licensing of biological substances for the purposes of drug discovery and diagnostic development; and pharmaceutical manufacturers of prescription or over-the counter drugs, including vaccines and development and manufacturing companies.

Why Invest In Junior Biotech?

Junior biotech companies, with a market capitalization that is less than $5 billion, have the potential advantage of a Food and Drug Administration more receptive to new cutting-edge and rare-disease therapies. They are possibly also strengthened by increased patient lobbying and greater willingness by insurers to pay for treatments. Combined with the potential for mergers-and-acquisitions and the U.S. government’s recent gigantic Covid-19 aid to small and mid-sized companies, small-caps seemed likely to lead the domestic recovery.

The value of the global pharmaceutical market rose from about US$390 billion in 2001, to about US$1.25 trillion at the end of 2019.1

Whether for cancer research, or a vaccine or treatment for Covid-19, we believe the strong demand side continues to combine with government regulation and policies prioritizing these sectors.

In uncertain and unpredictable times, biotechnology benchmarks have been known to beat the wider market.2

1 “Revenue of the worldwide pharmaceutical market from 2001 to 2019,” Statista, https://www.statista.com/statistics/263102/pharmaceutical-market-worldwide-revenue-since-2001/

2 “Biotech ETFs in the Spotlight, Why They’ll Remain There,” Tom Lydon, ETF Trends, June 18, 2020, https://www.etftrends.com/etf-building-blocks-channel/biotech-etfs-in-the-spotlight-why-they-can-remain-there/

* Commissions may be charged on trades.

Fund Data and Pricing

Net Assets $7.68M
Premium/discount -0.04%
NAV $30.71
Closing Price $30.70
Shares Outstanding 250,000
Median 30 Day Spread 0.32%
Data as of 05/05/2021

Fund Details

Fund inception 08/03/2020
Ticker IBBJ
Primary Exchange NASDAQ
CUSIP 26922A149
Fund Holdings 240
NAV Symbol IBBJ.NV
Expense Ratio 0.45%
30 Day SEC Yield* (0.42)%
* Yield as of 4/30/21
IBBJ
YTD 1 Months 3 Months 6 Months 1 Year Since Inception
Total Return (%) 4.54% 0.62% 16.06% 43.08% xx.xx% 45.20%
Market Price (%) 4.76% 1.06% 16.63% 43.15% xx.xx% 45.58%
1 Year Since Inception
Total Return (%) xx.xx% xx.xx%
Market Price (%) xx.xx% xx.xx%
YTD 1 Months 3 Months 6 Months 1 Year Since Inception
Total Return (%) -4.39% -0.81% -7.97% 21.67% xx.xx% 32.80%
Market Price (%) -4.24% -0.78% -7.92% 22.10% xx.xx% 33.07%
1 Year Since Inception
Total Return (%) xx.xx% xx.xx%
Market Price (%) xx.xx% xx.xx%
YTD 1 Months 3 Months 6 Months 1 Year Since Inception
Total Return (%) -3.61% -7.79% -3.61% 28.73% xx.xx% 33.89%
Market Price (%) -3.48% -7.56% -3.48% 28.80% xx.xx% 34.12%
1 Year Since Inception
Total Return (%) xx.xx% xx.xx%
Market Price (%) xx.xx% xx.xx%
YTD 1 Months 3 Months 6 Months 1 Year Since Inception
Total Return (%) xx.xx% 2.48% xx.xx% xx.xx% xx.xx% 4.01%
Market Price (%) xx.xx% 2.21% xx.xx% xx.xx% xx.xx% 3.94%
1 Year Since Inception
Total Return (%) xx.xx% xx.xx%
Market Price (%) xx.xx% xx.xx%
YTD 1 Months 3 Months 6 Months 1 Year Since Inception
Total Return (%) xx.xx% 14.62% 23.28% xx.xx% xx.xx% 25.11%
Market Price (%) xx.xx% 14.78% 22.74% xx.xx% xx.xx% 24.82%
1 Year Since Inception
Total Return (%) xx.xx% xx.xx%
Market Price (%) xx.xx% xx.xx%
YTD 1 Months 3 Months 6 Months 1 Year Since Inception
Total Return (%) 3.90% 3.90% 32.21% xx.xx% xx.xx% 44.31%
Market Price (%) 3.66% 3.66% 32.45% xx.xx% xx.xx% 44.04%
1 Year Since Inception
Total Return (%) xx.xx% xx.xx%
Market Price (%) xx.xx% xx.xx%
YTD 1 Months 3 Months 6 Months 1 Year Since Inception
Total Return (%) xx.xx% xx.xx% xx.xx% xx.xx% xx.xx% 1.49%
Market Price (%) xx.xx% xx.xx% xx.xx% xx.xx% xx.xx% 1.69%
1 Year Since Inception
Total Return (%) xx.xx% xx.xx%
Market Price (%) xx.xx% xx.xx%
YTD 1 Months 3 Months 6 Months 1 Year Since Inception
Total Return (%) xx.xx% 4.95% xx.xx% xx.xx% xx.xx% 9.15%
Market Price (%) xx.xx% 4.63% xx.xx% xx.xx% xx.xx% 8.75%
1 Year Since Inception
Total Return (%) xx.xx% xx.xx%
Market Price (%) xx.xx% xx.xx%
YTD 1 Months 3 Months 6 Months 1 Year Since Inception
Total Return (%) xx.xx% 11.02% 33.55% xx.xx% xx.xx% 38.90%
Market Price (%) xx.xx% 11.33% 33.69% xx.xx% xx.xx% 38.96%
1 Year Since Inception
Total Return (%) xx.xx% xx.xx%
Market Price (%) xx.xx% xx.xx%
2020
Total Return (%) xx.xx%
Market Price (%) xx.xx%
The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. Performance current to the most recent month-end can be obtained by calling 833.333.9383. Short term performance, in particular, is not a good indication of the fund’s future performance, and an investment should not be made based solely on returns. Market price is the price at which shares in the ETF can be brought or sold on the exchanges during trading hours, while the net asset value (NAV) represents the value of each share’s portion of the fund’s underlying assets and cash at the end of the trading day.
Name Symbol Stock price % Net assets Shares Held Market Value
Zai Lab Ltd ZLAB $155.58 2.89% 1,405 218,590
Bridgebio Pharma Inc BBIO $49.59 2.30% 3,505 173,813
Fate Therapeutics Inc FATE $76.55 2.23% 2,205 168,793
Halozyme Therapeutics Inc HALO $47.69 2.01% 3,190 152,131
Medpace Hldgs Inc MEDP $163.91 1.82% 840 137,684
Vir Biotechnology Inc VIR $41.61 1.66% 3,010 125,246
Allakos Inc ALLK $99.15 1.62% 1,235 122,450
Kodiak Sciences Inc KOD $101.84 1.60% 1,190 121,190
Twist Bioscience Corp TWST $104.3 1.58% 1,145 119,424
Pacific Biosciences Calif Inc Com PACB $24.36 1.46% 4,545 110,716
Data as of 05/07/2021. Fund holdings are subject to change at any time and should not be considered recommendations to buy or sell any security.
View full holdings
Download Fund Documents
Investment Case
Fact Sheet
Index Methodology Guide
Prospectus
Summary Prospectus
SAI
Premium Discount Graph
Annual Report
Q2 Quarterly Holdings

Reasons to invest in IBBJ

Performance.

The record shows junior biotech stocks beating their senior counterparts over the last six months.

US leads in global pharma innovation.

Strong R&D budgets bring results. The US produced almost half of all biotech patents filed from 1999 to 2013.

Large cap pharma firms cash heavy and looking to invest.

The ten largest biotech/pharma companies in the S&P 500 had an average cash stockpile of $10.7 billion as of mid-June, 2020.

Patent cliff.

Pharma giants look for new revenue flows as their exclusive rights to existing patents dwindle.